1![Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision](https://www.pdfsearch.io/img/7a527d622eeb09346d84f6ca66c8ec89.jpg) | Add to Reading ListSource URL: protectbenefitrisk.euLanguage: English - Date: 2014-07-16 01:09:14
|
---|
2![Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 1 to Wave 1 Case Study Report 1:b:iii: Raptiva® (efalizumab) Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 1 to Wave 1 Case Study Report 1:b:iii: Raptiva® (efalizumab)](https://www.pdfsearch.io/img/fd1543ea198da850b1e8a43e43480e81.jpg) | Add to Reading ListSource URL: protectbenefitrisk.euLanguage: English - Date: 2014-07-16 01:09:12
|
---|
3![Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:iii Benefit - Risk Wave 1 Case Study Report: Raptiva® (efalizumab) Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:iii Benefit - Risk Wave 1 Case Study Report: Raptiva® (efalizumab)](https://www.pdfsearch.io/img/522297e9f12f83969f007b563fdf59e6.jpg) | Add to Reading ListSource URL: protectbenefitrisk.euLanguage: English - Date: 2014-07-16 01:09:12
|
---|
4![Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence *Not reported](https://www.pdfsearch.io/img/30c6a423cb1c3b12e1977fb2142294f0.jpg) | Add to Reading ListSource URL: patients.aan.comLanguage: English - Date: 2009-11-10 12:34:40
|
---|
5![FDA Patient Safety News: Show #83, February 2009 FDA Patient Safety News: Show #83, February 2009](https://www.pdfsearch.io/img/ab32cd4e8108935701bdcf6779427f53.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
6![RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of](https://www.pdfsearch.io/img/3dabbc364a78b4ecb1d8310ad43d732d.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 14:51:38
|
---|
7![RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of](https://www.pdfsearch.io/img/5f9403af3b946944dc03381d5599886f.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|